SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Charlotte Brontë

PatientCharlotte Brontë
Date of birth1987-04-21
IdentifiersMRN HR-NI025-SYN; SSN (made up) 000-25-3804
Document date2026-02-10
AuthorEleanor Thwaite, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review at 11 weeks, nine days after discharge from an admission for hyperemesis gravidarum. [S]

History of Present Illness

Ms. Brontë returns at 11 weeks 1 day. After the sick visit she was admitted for three nights for intravenous saline with potassium, thiamine, magnesium, ondansetron, and enoxaparin, and went home nine days ago keeping down fluids, food, and tablets. She takes ondansetron 4 mg every 8 hours, doxylamine-pyridoxine four tablets a day, and thiamine 100 mg three times a day. She now vomits once a day or less and eats five small meals a day. Her PUQE-24 score is 9. She has mild constipation since starting ondansetron, which she manages with fluids, prunes, and oat bran. She has had no headache, palpitations, pain, or bleeding. She felt low and frightened in the hospital and is now more hopeful. The planned electrolyte check within a week of discharge was not done; blood was drawn today. [S]

ElementDetail
Hospital courseThree nights: intravenous fluids, potassium, magnesium, thiamine, ondansetron, enoxaparin
Interval changeVomiting once a day or less; five small meals a day
PUQE-249 (moderate), down from 14
Side effectsMild constipation on ondansetron
MoodMore hopeful; EPDS 9

Review of Systems

SystemResultFinding
GastrointestinalPositiveNausea in the mornings; vomiting once a day or less; mild constipation
CardiovascularNegativeNo palpitations or fainting
NeurologicalNegativeNo headache, confusion, or unsteadiness
GenitourinaryNegativeNo bleeding or urinary symptoms
PsychiatricPositiveWas low and frightened in hospital; more hopeful now; no thoughts of self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Folic acid 0.4 mg oral tablet, one tablet by mouth daily (replacing an iron-containing prenatal vitamin while nausea is severe)One tablet by mouth dailyOral route2026-01-13activeS
Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, two tablets by mouth at bedtimeTwo tablets by mouth at bedtimeOral route2026-01-13 to 2026-01-20completedS
Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, one tablet in the morning, one mid-afternoon, and two at bedtime (four a day)One tablet in the morning, one mid-afternoon, and two at bedtimeOral route2026-01-20activeS
Metoclopramide 10 mg oral tablet, one tablet by mouth three times a day before mealsOne tablet by mouth three times a day, 30 minutes before mealsOral route2026-01-20 to 2026-01-29completedS
Sodium chloride 0.9% with potassium chloride 20 mmol per liter, 1000 mL intravenously over 8 hours1000 mL over 8 hours, guided by daily electrolytesIntravenous route2026-01-29 to 2026-02-01completedS
Thiamine 100 mg intravenously daily, the first dose before any dextrose100 mg intravenously once daily; first dose before any dextrose-containing fluidIntravenous route2026-01-29 to 2026-02-01completedS
Ondansetron 4 mg intravenously every 8 hours4 mg by slow intravenous injection every 8 hoursIntravenous route2026-01-29 to 2026-02-01completedS
Enoxaparin 20 mg subcutaneously once daily during the admission (weight under 50 kg)20 mg (0.2 mL) subcutaneously once daily while in hospitalSubcutaneous route2026-01-29 to 2026-02-01completedS
Magnesium sulfate 2 g in 50 mL intravenously over 1 hour, once2 g intravenously over 1 hour, one doseIntravenous route2026-01-29 to 2026-01-29completedS
Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hoursOne tablet on the tongue every 8 hoursOral route2026-02-01 to 2026-02-24completedS
Thiamine 100 mg oral tablet, one tablet by mouth three times a dayOne tablet by mouth three times a day while intake is poorOral route2026-02-01 to 2026-02-24completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-02-10Body height152cmS
2026-02-10Body weight43.6kgS
2026-02-10Body mass index (BMI) [Ratio]18.9kg/m2S
2026-02-10Systolic blood pressure104mm[Hg]S
2026-02-10Diastolic blood pressure64mm[Hg]S
2026-02-10Heart rate86/minS
2026-02-10Respiratory rate14/minS
2026-02-10Body temperature36.7CelS
2026-02-10Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-02-10Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
2026-02-10Potassium [Moles/volume] in Serum or Plasma4mmol/L3.5-5.1 mmol/LNormalS
2026-02-10Chloride [Moles/volume] in Serum or Plasma101mmol/L98-107 mmol/LNormalS
2026-02-10Carbon dioxide, total [Moles/volume] in Serum or Plasma25mmol/L22-29 mmol/LNormalS
2026-02-10Urea nitrogen [Mass/volume] in Serum or Plasma9mg/dL6-20 mg/dLNormalS
2026-02-10Creatinine [Mass/volume] in Serum or Plasma0.55mg/dL0.4-0.9 mg/dLNormalS
2026-02-10Glucose [Mass/volume] in Serum or Plasma82mg/dL70-99 mg/dLNormalS
2026-02-10Magnesium [Mass/volume] in Serum or Plasma1.9mg/dL1.7-2.2 mg/dLNormalS
2026-02-10Phosphate [Mass/volume] in Serum or Plasma3.4mg/dL2.5-4.5 mg/dLNormalS
2026-02-10Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L7-35 U/LNormalS
2026-02-10Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L10-35 U/LNormalS
2026-02-10Total score [EPDS]9{score}S

Physical Exam

Vital signs recorded on 2026-02-10; see the Vital Signs section. [S]

SystemFinding
GeneralSlight; better color; comfortable
HydrationMoist mucous membranes; pulse 86
AbdomenSoft and non-tender; uterus just palpable above the pubic bone
FetalFetal heart heard by handheld Doppler at 158 per minute

Problems

ProblemClinical statusVerificationCodeProvenance
First pregnancy at 38 (elderly primigravida), single live intrauterine pregnancy dated by ultrasound at 7 weeks 1 dayactiveconfirmed O09.519S — Synthetic modern prenatal care anchored to the documented report that she was pregnant when she died; the pregnancy itself is questioned in one source (CLM-0019).
Nausea and vomiting of pregnancy, moderate (PUQE-24 score 10), with early weight loss, under evaluation for hyperemesis gravidarumresolvedconfirmed O21.9S — Synthetic presenting concern at the index visit, superseded by the hyperemesis gravidarum diagnosis at the sick visit; her documented "perpetual nausea" is D and the hyperemesis reading of it is R.
Hyperemesis gravidarum with metabolic disturbance: unable to keep fluids down, 7.4 percent weight loss, dehydration, hypokalemia, hyponatremia, hypochloremic alkalosis, low magnesium, and raised transaminases; PUQE-24 score 14activeconfirmed O21.1S — Synthetic modern diagnosis linked to her documented final illness and the retrospective hyperemesis interpretation; it is not asserted as her historical diagnosis.
Gestational transient thyrotoxicosis: suppressed TSH and mildly raised free T4 with hyperemesis, no goiter, eye signs, or tremor; no treatment neededactiveconfirmed O99.281S — Synthetic finding that teaches the thyroid tests in hyperemesis; it echoes no documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPUQE-24 score (recorded in the note; no LOINC code found)Every visit while nausea and vomiting lastCompleted today9 (moderate), down from 14 at the sick visit
ExaminationWeight against pre-pregnancy weight (46.0 kg), pulse, blood pressure, and hydrationEvery visit while nausea and vomiting lastCompleted today43.6 kg, up 1.0 kg; pulse 86; well hydrated
LaboratoryElectrolytes, urea nitrogen, creatinine, and glucoseWhen vomiting is moderate or severe, daily while on intravenous fluids, and until stable on oral intakeCompleted todayNormal
LaboratoryElectrolytes within a week of dischargeOnce, within seven days of dischargeDeferredMissed: the check planned for within a week of discharge was not booked, and the first post-discharge electrolytes were drawn today, nine days after discharge. No harm: all results today are normal. Corrective action: discharge orders for hyperemesis now include a booked laboratory appointment
LaboratoryMagnesium and phosphate (refeeding risk)During admission and after refeeding beginsCompleted todayMagnesium 1.9 and phosphate 3.4 mg/dL: normal; no refeeding drop
LaboratoryALT and ASTUntil normal if raisedCompleted todayALT 31 and AST 24 U/L: normal
LaboratoryTSH and free T4In hyperemesis gravidarum; repeat at 16 to 18 weeks if suppressedDueSuppressed at the sick visit; repeat planned at 16 to 18 weeks
Medication safetyAntiemetic effects: constipation, headache, and palpitations with ondansetron; drowsiness with doxylamine-pyridoxineEvery visit and after each changeCompleted todayMild constipation only
Medication safetyThiamine while intake is poorFrom admission until regular mealsCompleted today100 mg three times a day; no signs of Wernicke encephalopathy
ExaminationVenous thromboembolism risk assessmentAt every admission and discharge, and at 28 weeksCompleted todayAge over 35 is her only persisting risk factor; no prophylaxis now
SurveyPerinatal mood screenEach trimester and after any admissionCompleted todayEPDS 9; item 10 scored 0
LaboratoryCell-free DNA screeningFrom 10 weeks, as she choseOrderedDrawn today; result in about a week
ExaminationBlood pressureEvery prenatal visitCompleted today104/64 mmHg
ExaminationFetal heartEvery prenatal visitCompleted today158 per minute by Doppler

Goal progress:

Guideline basis: ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy (2018); The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69) (2024); Reducing the Risk of Thrombosis and Embolism during Pregnancy and the Puerperium (Green-top Guideline No. 37a) (2015); Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226 (2020); Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum (Clinical Practice Guideline No. 4) (2023)

Follow-up: Prenatal visit with the nuchal translucency scan in two weeks, at 13 weeks. Next scheduled visit 2026-02-24: prenatal visit at 13 weeks with the nuchal translucency scan and the low-dose aspirin decision. [S]